Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Polycystic Ovary Syndrome 2Hyperandrogenism 1

Interventions

Saline Solution 10Docetaxel 10Bevacizumab 9nilotinib 8enzalutamide 8Paclitaxel 8Letrozole 8Fentanyl 8Everolimus 8Cyclophosphamide 8Carboplatin 8Bupivacaine 8Lidocaine 7Sodium Chloride 6Oxycodone 6Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 6Erlotinib Hydrochloride 6Dexamethasone 6Capecitabine 6Trastuzumab 5Tobacco Use Cessation Devices 5Surveys and Questionnaires 5Nivolumab 5Hydromorphone 5Adalimumab 5fludarabine 4Zoledronic Acid 4Tranexamic Acid 4Tacrolimus 4Rocuronium 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Has results × drospirenone and ethinyl estradiol combination × Clear all
NCT03819140 2025-11-14

CCOUP

University of California, San Francisco

Phase 4 Completed
51 enrolled 15 charts

Polycystic Ovary Syndrome, Hyperandrogenism

NCT00640224 2017-11-17

Insulin Resistance, Polycystic Ovary Syndrome, and Bone Research Study

University of Pittsburgh

Phase 4 Completed
65 enrolled 28 charts

Polycystic Ovary Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡